Effects of the perimenopausal period on the course of heart failure

Basit Öğe Kaydı
dc.authoridGenc, Ahmet/0000-0003-0797-8418
dc.authoridOzen, Mehmet/0000-0002-6075-1733
dc.authoridSahin, Anil/0000-0003-3416-5965
dc.authoridYilmaz Oztekin, Gulsum Meral/0000-0001-9540-5075
dc.contributor.authorSahin, Emine Tugce
dc.contributor.authorOztekin, Gulsum Meral Yilmaz
dc.contributor.authorGenc, Ahmet
dc.contributor.authorSahin, Anil
dc.contributor.authorOzen, Mehmet
dc.date.accessioned2024-10-26T18:00:43Z
dc.date.available2024-10-26T18:00:43Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: It is known that the decrease in estrogen level in women's life has negative effects on the cardiovascular system. In this study, it was aimed to elucidate the changes in the clinical status and treatment requirement of patients with heart failure (HF) during the menopausal transition period.Materials and Methods: A total of 26 patients followed up in the HF outpatient clinic between 2015-2020 were included in this retrospective, single-center study. Demographic data of the patients, New York Heart Association class, echocardiographic findings, routine biochemical parameters and HF signs, symptoms and therapies were examined. Data at the beginning of the menopause period and after 12 months were compared.Results: At the end of the 12-month follow-up, a statistically significant increase was found in the daily dose of furosemide (50.5 mg/day vs. 72.4 mg/day). While the mean heart rate of the patients was 80.4 +/- 20.1 beats/min at the beginning, it was 69.3 +/- 10.1 beats/min in the control visit. Echocardiographically measured left ventricular (LV) systolic diameters of the patients were significantly increased compared to baseline in the control visit (41.2 +/- 7.4 mm vs 45.8 +/- 7.0 mm,).Conclusion: The menopausal period caused an increase in the need for treatment in patients followed up with HF. Therefore, in evaluation of the patients with HF, it would be a useful approach to question the menopausal status in detail and to follow the patients more closely during the menopausal transition period.
dc.identifier.doi10.17826/cumj.1186283
dc.identifier.endpage144
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue1
dc.identifier.startpage136
dc.identifier.trdizinid1181508
dc.identifier.urihttps://doi.org/10.17826/cumj.1186283
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1181508
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27825
dc.identifier.volume48
dc.identifier.wosWOS:000960019300016
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherCukurova Univ, Fac Medicine
dc.relation.ispartofCukurova Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEstrogen
dc.subjectheart failure
dc.subjectmenopause
dc.titleEffects of the perimenopausal period on the course of heart failure
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu